Biomarkers of Injectable Extended Release Naltrexone Treatment
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the biological markers of treatment of opioid dependent individuals with
an extended release formulation of the opioid antagonist naltrexone. The biological measures
include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and
behavioral tests probing various aspects of personality, memory, reward processing and
attention.